Get the Daily Brief
Latest Biotech News
Recursion names Najat Khan CEO as cash runway extends into 2027
Recursion announced a leadership transition and mixed Q3 results: co‑founder Chris Gibson will become chairman while Najat Khan is set to take over as CEO. The company reported a larger net loss...
Amae Health raises $25M Series B to expand severe mental‑illness care
Behavioral‑health startup Amae Health closed a $25 million Series B led by Altos Ventures with participation from Quiet Capital, Bling Capital, Cedars‑Sinai Ventures, Healthier Capital and 8VC....
Patient advocates urge incentives for genetically targeted technologies (GTTs)
At BIO 2025’s PACE event, patient advocates and industry leaders pushed for policy incentives to protect development of genetically targeted technologies such as antisense oligonucleotides (ASOs)....
Sequential PD‑1 inhibitors improve outcomes after CD19 CAR‑T consolidation
A recent study led by Xue, Zhou and Chen found that using PD‑1 inhibitors as consolidative therapy after CD19 CAR‑T improved outcomes for patients with relapsed or refractory non‑Hodgkin lymphoma....
Toripalimab plus FLOT shows activity in peritoneal‑metastatic gastric cancer
A phase II trial reported that adding toripalimab, an anti‑PD‑1 antibody, to the FLOT chemotherapy backbone produced encouraging responses in gastric cancer patients with peritoneal metastasis....
Pfizer seals $10 billion takeover: Metsera deal ends bidding war
Pfizer agreed to buy obesity-drug developer Metsera for about $10 billion, topping a rival offer from Novo Nordisk and resolving a public bidding fight. The proposal offers up to $86.25 per share...
Merck’s oral PCSK9 pill slashes LDL up to 60%: Phase 3 data
Merck reported Phase 3 results showing its oral PCSK9 inhibitor reduced LDL cholesterol by as much as 60% in patients already on statins, meeting its long-sought goal of matching injectable...
Early CRISPR gene-editing lowers lipids in humans... but safety questions remain
An early-stage CRISPR-based therapy dramatically reduced LDL cholesterol and triglycerides in a small cohort of patients with heart disease, investigators reported at the American Heart...
Amgen’s Repatha prevents first heart attacks: detailed VESALIUS-CV results
Amgen disclosed detailed VESALIUS-CV trial data showing its PCSK9 monoclonal antibody Repatha reduced major cardiovascular events by 25% and prevented first heart attacks by 36% in high-risk...
Vir presents hepatitis D combo data: Phase 3 program accelerated
Vir Biotechnology reported new data showing its combination regimen for chronic hepatitis D maintains low viral levels, reinforcing the therapy’s potential as clinical studies advance. The company...
Recursion names new CEO as losses widen — cash runway extended to 2027
AI-driven drug developer Recursion announced a leadership transition and an improved cash position that extends runway into 2027. Co-founder Chris Gibson will step down as CEO to become board...
Amae Health raises $25M to scale care for severe mental illness
Amae Health closed a $25 million Series B led by Altos Ventures with participation from Quiet Capital, Bling Capital, Cedars-Sinai Ventures, Healthier Capital and 8VC to expand its care model for...
PD‑1 inhibitors as consolidation after CD19 CAR‑T improve lymphoma outcomes
A study led by Xue, Zhou and Chen reports that sequential PD‑1 inhibitor therapy given after CD19 CAR‑T cell treatment enhances outcomes in relapsed and refractory non-Hodgkin lymphoma. The...
Targeted vitamin D3 halved repeat heart attacks in post-MI patients: TARGET-D trial
Intermountain Health’s TARGET-D randomized trial found measured, personalized vitamin D3 supplementation cut the risk of a repeat heart attack by roughly 50% in patients who previously experienced...
Toripalimab plus FLOT shows promise in metastatic gastric cancer with peritoneal spread
A phase II trial reported that adding toripalimab, an anti‑PD‑1 antibody, to standard FLOT chemotherapy produced encouraging responses in patients with metastatic gastric cancer involving...
Pfizer ups bid and clinches Metsera: $10B takeover ends obesity duel
Pfizer submitted an increased cash offer and won the bidding war for Metsera, the obesity-drug developer, topping rival Novo Nordisk and securing a deal valued at about $10 billion. Pfizer offered...
Merck’s oral PCSK9 pill slashes LDL by up to 60%: late‑stage win
A Phase 3 trial presented in New Orleans found Merck’s oral PCSK9 inhibitor produced LDL reductions up to 60% versus placebo in patients already on statins, meeting its primary endpoints across...
Repatha prevents first heart attacks – Amgen posts 25% event reduction
Amgen reported new VESALIUS‑CV data showing its PCSK9 monoclonal antibody Repatha reduced major cardiovascular events by 25% when added to standard therapy in high‑risk patients without prior...
CRISPR therapy trims LDL and triglycerides in early human test…safety questions linger
An early clinical study of a CRISPR‑based gene editing therapy produced dramatic reductions in LDL cholesterol and triglycerides in a small cohort, signaling potential for one‑time editing to...
FDA expands fast‑track pilot: six more drugs added to national‑interest review
The FDA added six additional therapies to its Commissioner’s National Priority Voucher pilot, bringing the program’s total to 15 drugs slated for accelerated review. The agency said the pilot aims...